Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04116021
Other study ID # PECS 2019
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date November 1, 2019
Est. completion date June 30, 2021

Study information

Verified date October 2019
Source Hôpital du Valais
Contact Sina Grape, MD
Phone 0041276038759
Email sina.grape@hopitalvs.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial will include patients undergoing radical mastectomy under general anesthesia. One group of patients will receive a pectoral nerve block, done by the anesthetist under ultrasound guidance at the beginning of the invervention. The other group will receive the a wound infiltration at the end of the intervention, done by the surgeon. Investigators will compare acute pain-related outcomes and chronic pain at 3 and 6 months postoperatively.


Description:

Mastectomies are associated with moderate to severe postoperative pain. In addition to general anesthesia, different methods of locoregional anesthesia exist to treat postoperative pain, amongst others a pectoral nerve block. This block consists in injecting local anesthetic between the muscles of the thoracic wall and is done under ultrasound guidance. Over the last few years, the pectoral nerves block has become a recognized option for the treatment of acute post-mastectomy pain and it is routinely performed in addition to general anesthesia.

Data indicates that pectoral nerve blocks are effective for the treatment of postoperative pain during the first 24 hours after mastectomy, when compared to no block. However, the analgesic efficacy of a pectoral nerve block has never systematically compared to that of wound infiltration with local anesthetics, done by the surgeon at the end of the intervention. Such an infiltration is also currently employed.

In our study randomize patients undergoing mastectomy under general anesthesia will be randomized to receive either an ultrasound-guided pectoral nerve block with 30 mL of local anesthetic (group PECS) or a wound infiltration with 30 mL of local anesthetic (group infiltration).

Investigators will assess different pain-related outcomes over the first 24 postoperative hours, together with potential block-related side effects and patient satisfaction. Chronic postoperative pain at 3 and 6 months postoperatively will also be assessed.

Both patients and outcome assessors will be blinded to group allocation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date June 30, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients undergoing unilateral mastectomy

- American Society of Anesthesiology Physical Status I-III

- Age = 18

Exclusion Criteria:

- Contraindications to regional anesthesia, such as infection at the surgical site

- Pregnancy

- History of alcohol or drug dependence/abuse

- History of long term opioid intake

- Chronic pain disorder

Study Design


Related Conditions & MeSH terms


Intervention

Other:
PECS block
Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
Local infiltration
Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Hôpital du Valais University of Lausanne Hospitals

Outcome

Type Measure Description Time frame Safety issue
Primary Morphine consumption Cumulative intravenous morphine consumption (mg) first 24 postoperative hours
Secondary Pain score at rest at 2 hours postoperatively Numeric rating scale from 0 = no pain to 10 = worst imaginable pain 2 hours postoperatively
Secondary Pain score at rest at 12 hours postoperatively Numeric rating scale from 0 = no pain to 10 = worst imaginable pain 12 hours postoperatively
Secondary Pain score at rest at 24 hours postoperatively Numeric rating scale from 0 = no pain to 10 = worst imaginable pain 24 hours postoperatively
Secondary Pain score on movement at 2 hours postoperatively Numeric rating scale from 0 = no pain to 10 = worst imaginable pain 2 hours postoperatively
Secondary Pain score on movement at 12 hours postoperatively Numeric rating scale from 0 = no pain to 10 = worst imaginable pain 12 hours postoperatively
Secondary Pain score on movement at 24 hours postoperatively Numeric rating scale from 0 = no pain to 10 = worst imaginable pain 24 hours postoperatively
Secondary Time to first analgesic request Time between end of surgery and first analgesic request by patient, in minutes 24 hours postoperatively
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2